Anti PD-1 treatment increases [F]FDG uptake by cancer cells in a mouse B16F10 melanoma model

about

Anti PD-1 treatment increases [F]FDG uptake by cancer cells in a mouse B16F10 melanoma model

Item

http://www.wikidata.org/entity/Q58774383

description

scientific article published on 16 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Anti PD-1 treatment increases ...... a mouse B16F10 melanoma model

@en

Anti PD-1 treatment increases ...... a mouse B16F10 melanoma model

@nl

type

Item

label

Anti PD-1 treatment increases ...... a mouse B16F10 melanoma model

@en

Anti PD-1 treatment increases ...... a mouse B16F10 melanoma model

@nl

prefLabel

Anti PD-1 treatment increases ...... a mouse B16F10 melanoma model

@en

Anti PD-1 treatment increases ...... a mouse B16F10 melanoma model

@nl

P1476

Anti PD-1 treatment increases ...... a mouse B16F10 melanoma model

@en

P2093

Hideo Takakura

http://www.w3.org/2001/XMLSchema#string

Kei Higashikawa

http://www.w3.org/2001/XMLSchema#string

Kohei Nakajima

http://www.w3.org/2001/XMLSchema#string

Mayu Tomita

http://www.w3.org/2001/XMLSchema#string

Tohru Shiga

http://www.w3.org/2001/XMLSchema#string

Yuji Kuge

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Metabolic pathways in T cell activation and lineage differentiation

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

The Warburg Effect: How Does it Benefit Cancer Cells?

Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.

Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog.

Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy

Clinical significance of diffusely increased splenic uptake on FDG-PET.

The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.

P2888

s13550-018-0433-1

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13550-018-0433-1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hironobu Yasui

Mikako Ogawa

P577

2018-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1106154452

http://www.w3.org/2001/XMLSchema#string

P698

30117062

http://www.w3.org/2001/XMLSchema#string

P932

6095935

http://www.w3.org/2001/XMLSchema#string